Detalhe da pesquisa
1.
In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Future Oncol
; 20(3): 131-143, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37807952
2.
Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination.
Ann Pharmacother
; 48(2): 292-6, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24259648
3.
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Blood Cancer J
; 13(1): 147, 2023 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37726298
4.
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Clin Lymphoma Myeloma Leuk
; 20(11): e910-e925, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32912820
5.
Practical strategies for creating diversity, equity, inclusion, and access in cancer clinical research: DRIVE.
Blood Adv
; 7(8): 1507-1512, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36005840